Journal Article Meta-Analysis Epublish
PubMed: 40055767 DOI: 10.1186/s12957-025-03716-2
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis.
World J Surg Oncol 23(1):77
Authors: Li Yanbing, Li Zijun, Zuo Hongbo, Wang Zhi
Affiliations
- Department II of Oncology, The First People'S Hospital of Jiujiang, Jiujiang city, Jiangxi province, 332000, China.
- Department II of Oncology, The First People'S Hospital of Jiujiang, Jiujiang city, Jiangxi province, 332000, China.
Abstract
OBJECTIVE
This meta-analysis aimed to evaluate the dose-response relationship between body mass index (BMI) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
METHODS
We conducted a dose-response meta-analysis of 10 studies involving 6,841 cancer patients. Studies reporting BMI and CIPN outcomes were selected. The relationship between BMI and CIPN was assessed using random-effects models and restricted cubic splines to model the dose-response association.
RESULTS
Pooled analysis revealed a significant association between higher BMI and increased risk of CIPN, with an odds ratio (OR) of 1.55 (95% CI, 1.20-1.99). A dose-response analysis demonstrated a clear linear relationship between BMI and the risk of CIPN. For every 5Â kg/m 2 increase in BMI, the relative risk of CIPN increased by approximately 15%. Subgroup analyses showed stronger associations in breast cancer patients and those treated with taxane or platinum-based regimens. Sensitivity analyses confirmed the robustness of the results, and mild publication bias was observed.
CONCLUSIONS
Higher BMI is significantly associated with an increased risk of CIPN, with a dose-dependent effect. Weight management interventions, such as dietary modifications and physical activity, may reduce CIPN risk, particularly in patients with elevated BMI undergoing chemotherapy with neurotoxic regimens.
MeSH
Peripheral Nervous System Diseases, Neoplasms, Drug Therapy, Chemotherapy